Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Next Previous
Trial Profile

A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Dexamethasone
  • Indications Brain metastases; Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms CheckMate204
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress
  • 12 Oct 2023 According to Bristol Myers Squibb media release, data from this study has been selected for ESMO 2023.
  • 10 Nov 2021 Three-years follow-up results published in the Lancet Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top